| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| APBiotech, Inc. |
| 800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855 * (732) 457-8000 |
| Business Description | The company is a leading global provider of biotechnology systems, products and services for research into genes and proteins, for the discovery and development of drugs, and for the manufacture of biopharmaceuticals. |
|
Filing Information Not yet | |||
| To Trade As | APBI (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 10/2/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $100,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Morgan Stanley Dean Witter | Lead Manager | (212) 761-5900 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| Goldman, Sachs & Co. | Co-manager | (212) 902-5959 |
| Salomon Smith Barney | Co-manager | (212) 723-7300 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 3/31/96 | 3/31/97 | 12/31/98 | 12/31/99 | 6/30/99 | 6/30/00 | |
| Revenues | - | 244.900 | 260.000 | 729.400 | 864.100 | 375.900 | 449.200 |
| Income from Oper. | - | 41.800 | 44.400 | 18.000 | 32.200 | -2.900 | 12.100 |
| Net Income | - | 24.200 | 25.800 | -10.500 | -6.300 | 6.900 | -5.600 |
| E.P.S | - | 44.000 | 46.910 | -19.800 | -16.200 | 2.000 | -10.600 |
| Revenue Growth (%) | - | 6.17 | 180.54 | 18.467 | 19.50 | ||
| Net Income Growth (%) | - | 6.61 | - | - | - | ||
| Oper. Profit Margin (%) | - | 17.07 | 17.08 | 2.47 | 3.73 | 2.69 | - |
| Net Profit Margin (%) | - | 9.88 | 9.92 | - | - | - | 1.84 |
| Cash Flow - Oper. | - | -14.90 | 25.70 | ||||
| Cash Flow - Inv. | - | -30.60 | -33.70 | ||||
| Cash Flow - Fin. | - | 36.30 | 6.30 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/00 | Financial Ratios | ||||
| Total Assets | 1,208.70 | Current Assets | 441.80 | Current Ratio | 0.72 |
| Total Liab. | 882.40 | Current Liab. | 616.70 | Debt Ratio | 73.00% |
| Total Equity | 326.30 | Working Cap. | -174.90 | Debt to Equity Ratio | 2.70 |
| Cash | 27.50 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for general corporate purposes, primarily to fund operations, to repay indebtedness owed to Nycomed Amersham. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Davis, Polk & Wardwell |
| Bank's Law Firm | Shearman & Sterling |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Nycomed Amersham plc | ||
| Note: represents ownership of 5% or more prior to the offering. | ||